Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia

Karaman, Serap; Vural, Sema; Yıldırmak, Yıldız; Emecen, Merve; Erdem, Ela; Kebudi, Rejin

doi:10.1002/pbc.23245

Cited by 19 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The modification ratio was reported to be 20%-50% in several studies and our results were slightly higher than the published work. Factors affecting modification were neutrophil count less than 100 cells/mm 3 and the presence of severe mucositis which is consistent with previous reports (p<0.05) (Uygun et al, 2009;Karaman et al, 2012). Duration of neutropenia and remission status did not have an influence on modification ratio (p>0.05).…”

Section: Discussionsupporting

confidence: 82%

“…Paul et al (2010) have shown that ceftazidime, cefepime, PIP/TAZ, and carbapenems were effective as monotherapy in their meta-analysis. The results were in agreement with recent studies including pediatric cancer patients, reporting that cefozopran, cefepime, meropenem,imipenem, sulperazon and piperacillin-tazobactam were effective and safe for empiric treatment of febrile neutropenic episodes (Agaoglu et al, 2001;Corapcioglu et al, 2006;Erbey et al, 2009;Uygun et al, 2009;Vural et al, 2010;Demir et al, 2011;Erbey et al, 2010;Ichikawa et al, 2011;Karaman et al, 2012). Vural et al (2010) compared PIP/ TAZ versus imipenem in pediatric febrile neutropenia and reported that both antibiotics can be used safely as monotherapy.…”

Section: Discussionsupporting

confidence: 81%

“…Gulay Sezgin*, Can Acipayam, Ayse Ozkan, Ibrahim Bayram, Atila Tanyeli include anti-pseudomonal cephalosporins, carbapenems, ureidopenicillins, and cephalosporins combined with beta lactamase inhibitors (Agaoglu et al, 2001;Corapcioglu et al, 2006;Erbey et al, 2009;Uygun et al, 2009;Erbey et al, 2010;Vural et al, 2010;Demir et al, 2011;Ichikawa et al, 2011;Karaman et al, 2012).…”

Section: Meropenem Versus Piperacillin-tazobactam As Empiric Therapy mentioning

confidence: 99%

See 2 more Smart Citations

Meropenem Versus Piperacillin-Tazobactam as Empiric Therapy for Febrile Neutropenia in Pediatric Oncology Patients

Sezgin

Acıpayam²,

Özkan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Infection is a serious cause of mortality in febrile neutropenia of pediatric cancer patients. Recently, monotherapy has replaced the combination therapy in empirical treatment of febrile neutropenia. Since there has been no reported trial comparing the efficacy of meropenem and piperacillin-tazobactam (PIP/ TAZ) monotherapies, the present retrospective study was conducted to compare safety and efficacy in febrile neutropenic children with cancer. Materials and Methods: Charts of febrile, neutropenic children hospitalized at our center between March 2008 and April 2011 for hemato-oncological malignancies were reviewed. Patients received PIP/TAZ 360 mg/kg/day or meropenem 60 mg/kg/day intravenously in three divided doses. Duration of fever and neutropenia, absolute neutrophil count, modification, and success rate were compared between the two groups. Resolution of fever without antibiotic change was defined as success and resolution of fever with antibiotic change or death of a patient was defined as failure. Modification was defined as changing the empirical antimicrobial agent during a febrile episode. Results: Two hundred eighty four febrile neutropenic episodes were documented in 136 patients with a median age of 5 years. In 198 episodes meropenem and in 86 episodes PIP/ TAZ were used. Duration of fever and neutropenia, neutrophil count, sex, and primary disease were not different between two groups. Success rates and modification rate between two groups showed no significant differences (p>0.05). Overall success rate in the meropenem and PIP/TAZ groups were 92.4% and 91.9% respectively. No serious adverse effects occurred in either of the groups. Conclusions: Meropenem and PIP/TAZ monotherapy are equally safe and effective in the initial treatment of febrile neutropenia in children with cancer.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 81%

Section: Meropenem Versus Piperacillin-tazobactam As Empiric Therapy mentioning

confidence: 99%

See 1 more Smart Citation

Meropenem Versus Piperacillin-Tazobactam as Empiric Therapy for Febrile Neutropenia in Pediatric Oncology Patients

Sezgin

Acıpayam²,

Özkan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Febrile neutropenia (FN) is a common, but a serious complication with severe morbidity and mortality during the treatment of pediatric cancer. Although monotherapy using broad spectrum antibiotics is now a standard of care, there is currently no consensus on optimal agents.…”

Section: Introductionmentioning

confidence: 99%

A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders

Sano

Kobayashi

Suzuki

et al. 2016

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…9 ß-lactam/ß-lactamase inhibitor combinations like piperacillin-tazobactam and cefoperazonesulbactam have already proven to be good alternatives to treat patients with less severe sepsis, thus restricting usage of carbapenem only to severe life-threatening sepsis. [10][11][12] A recent metaanalysis concluded that piperacillin tazobactam can be a suitable alternative to carbapenems for treating patients with bloodstream infections due to ESBL-E. coli if active in vitro, to be used as definitive therapy. 4 Increase in carbapenem usage has a direct relationship to increase in carbapenem resistant Gram negative bacteria.…”

Section: Introductionmentioning

confidence: 99%

Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam/ß-lactamase inhibitor combination

Ghafur¹,

Tayade²,

Kannaian³

2012

JMID

View full text Add to dashboard Cite

Objectives: Cefepime/tazobactam is a new ß-lactam/ß-lactamase inhibitor combination licensed for clinical use by Drugs Controller General of India. Aim of our study was to analyze the clinical efficacy and safety of cefepime/tazobactam in patients with sepsis. To the best of our knowledge, this is the first published clinical study on this drug. Materials and methods:A retrospective observational study on the efficacy and safety of cefepime/tazobactam was conducted at a tertiary care hospital, South India. Patients who had a clear source of infection, having a single organism as the causative agent and being treated with cefepime/tazobactam alone were analyzed for efficacy and those cases who had a clear source of infection but either had multiple organism grown or cultures being negative or those patients who received a combination of antibiotics were analyzed for the safety analysis.Results: Thirty two patients satisfied our study criteria. All 15 patients in the efficacy group (nine with ventilator associated pneumonia, three tracheitis, two bacteraemia and one with urosepsis) had complete clinical cure, with microbiological cure in cases where a repeat culture was indicated. There were no significant side effects in any of the evaluable 32 patients assessed for safety. Gereç ve yöntem:Sefepim/tazobaktam'ın etkinlik ve güvenilirliği üzerine Güney Hindistan'da üçüncü basamak bir bakım merkezinde retrospektif bir gözlem çalışması yapıldı. Enfeksiyon kaynağı belli olan, tek bir mikroorganizmanın etken olarak izole edildiği ve tek başına sefepim/tazobaktam ile tedavi edilen hastalar etkinlik açısından incelendi ve belirgin bir enfeksiyon kaynağı olduğu halde birden çok organizma üreyen veya kültürü negatif olan yada tedavi için bir antibiyotik kombinasyonu alan hastalar güvenilirlilik analizi için incelendi.

show abstract

Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia

Abstract: CS and PIP/TAZO monotherapy are both safe and effective in the initial treatment of febrile neutropenia in children with cancer.

Cited by 19 publications

References 32 publications

Meropenem Versus Piperacillin-Tazobactam as Empiric Therapy for Febrile Neutropenia in Pediatric Oncology Patients

Meropenem Versus Piperacillin-Tazobactam as Empiric Therapy for Febrile Neutropenia in Pediatric Oncology Patients

A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders

Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam/ß-lactamase inhibitor combination

Contact Info

Product

Resources

About